A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia

被引：1
|
作者：
Shah, Bijal D. [1 ]
Rozario, Nicole [2 ]
Turba, Elyce P. [3 ]
Bello, Celeste [4 ]
Chavez, Julio C. [3 ]
Sokol, Lubomir [4 ]
Brayer, Jason [5 ]
Lancet, Jeffrey E. [6 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-151936
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4399
引用
收藏
页数：4
相关论文
共 50 条
  • [1] A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia
    Absalon, Michael J.
    Breese, Erin H.
    Lee, Lynn
    O'Brien, Maureen M.
    Phillips, Christine L.
    Burns, Karen
    Mizukawa, Benjamin
    An, Qi
    Mangino, Jennifer
    Kaplan, Joel
    Norris, Robin
    Perentesis, John Peter
    BLOOD, 2018, 132
  • [2] Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia
    O'Brien, Maureen M.
    Alonzo, Todd A.
    Cooper, Todd M.
    Levine, John E.
    Brown, Patrick A.
    Slone, Tamra
    August, Keith J.
    Benettaib, Bouchra
    Biserna, Noha
    Poon, Jennifer
    Patturajan, Meera
    Chen, Nianhang
    Simcock, Mathew
    Zimmerman, Linda
    Kolb, E. Anders
    PEDIATRIC BLOOD & CANCER, 2021, 68 (07)
  • [3] CPX-351 with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase Ib Study
    Bataller, Alex
    Bazinet, Alexandre
    Borthakur, Gautam
    Short, Nicholas J.
    Jabbour, Elias
    Takahashi, Koichi
    Daver, Naval
    Issa, Ghayas C.
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Jain, Nitin
    Montalban-Bravo, Guillermo
    Wierda, William G.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    BLOOD, 2023, 142
  • [4] Blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukaemia: An open-label, single-arm, multicenter confirmatory phase 2 study
    Topp, M. S.
    Goekbuget, N.
    Stein, A. S.
    Bargou, R. C.
    Dombret, H.
    Fielding, A. K.
    Ribera, J. M.
    Foa, R.
    Zugmaier, G.
    Jia, C.
    Maniar, T.
    Huber, B.
    Nagorsen, D.
    Kantarjian, H. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 181 - 181
  • [5] Phase I Open-Label Single-Arm Study of Sscart-19 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in China
    Kang, Liqing
    Xue, Shengli
    Tang, Xiaowen
    Lou, Xiaoyan
    Qian, Chongsheng
    Gong, Wenjie
    Xu, Mingzhu
    Zhou, Haixia
    Yao, Zhen
    Wang, Wei
    Li, Minghao
    Xu, Nan
    Yu, Zhou
    Chen, Suning
    Qiu, Huiying
    Dai, Haiping
    Xu, Yang
    Wu, Depei
    Yu, Lei
    BLOOD, 2023, 142
  • [6] Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study
    You, Liangshun
    Liu, Yi
    Mai, Wenyuan
    Xie, Wanzhuo
    Zhou, De
    Mao, Liping
    Chen, Lili
    Zhou, Xinping
    Ma, Liya
    Zheng, Xiaolong
    Wei, Juying
    Lou, Yinjun
    Ye, Xingnong
    Tong, Hongyan
    Jin, Jie
    Meng, Haitao
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [7] Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study
    Deng, Li-Juan
    Zhou, Ke-Shu
    Liu, Li-Hong
    Zhang, Ming-Zhi
    Li, Zhi-Ming
    Ji, Chun-Yan
    Xu, Wei
    Liu, Ting
    Xu, Bing
    Wang, Xin
    Gao, Su-Jun
    Zhang, Hui-Lai
    Hu, Yu
    Li, Yan
    Cheng, Ying
    Yang, Hai-Yan
    Cao, Jun-Ning
    Zhu, Zun-Min
    Hu, Jian-Da
    Zhang, Wei
    Jing, Hong-Mei
    Ding, Kai-Yang
    Zhang, Xiang-Yang
    Zhao, Ren -Bin
    Zhang, Bin
    Tian, Ya -Min
    Song, Yong-Ping
    Song, Yu-Qin
    Zhu, Jun
    BLOOD ADVANCES, 2023, 7 (16) : 4349 - 4357
  • [8] Everolimus for Relapsed/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study
    Johnston, Patrick B.
    Pinter-Brown, Lauren
    Rogerio, Jaqueline
    Warsi, Ghulam
    Chau, Quincy
    Ramchandren, Radhakrishnan
    BLOOD, 2012, 120 (21)
  • [9] V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia
    Agresta, Laura
    O'Brien, Maureen M.
    Mizuno, Kana
    Norris, Robin
    Breese, Erin H.
    Phillips, Christine L.
    Burns, Karen
    Mizukawa, Benjamin
    Lee, Lynn
    Lane, Adam
    Lorsbach, Robert B.
    Ryan, Thomas D.
    Desai, Pankaj B.
    Vinks, Alexander A.
    Grimes, H. Leighton
    Perentesis, John P.
    Absalon, Michael J.
    BLOOD, 2019, 134
  • [10] Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Bharathi, Vanthana
    Bataller, Alex
    Bazinet, Alexandre
    Borthakur, Gautam
    Jabbour, Elias
    Daver, Naval
    Short, Nicholas J.
    Takahashi, Koichi
    Issa, Ghayas C.
    Dinardo, Courtney D.
    Pemmaraju, Naveen
    Jain, Nitin
    Montalban-Bravo, Guillermo
    Wierda, William G.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    BLOOD, 2024, 144 : 4272 - 4274
12345